Worldwide, cardiovascular disease (CVD) remains the number one killer of men and women. In the United States, CVD leads to one in every three deaths – one death approximately every 38 seconds – with annual treatment cost in excess of $500 billion.
Multiple primary and secondary prevention trials have shown a significant reduction of 25% to 35% in the risk of cardiovascular events with statin therapy, leaving significant risk despite control of LDL-C levels. A new study has found that adding icosapent ethyl in addition to statin therapy can reduce cardiovascular events by up to 25%.
Learn more here.
